VRAX

Company Overview — What Does Virax Biolabs Group Ltd Do?

Virax Cayman is a holding company incorporated as an exempted company under the laws of the Cayman Islands. As a holding company with no material operations of our own, Virax Cayman conducts our operations through its operating subsidiaries in Singapore, Hong Kong, China and British Virgin Islands and has been operating since 2013. Prior to the introduction of Virax branded products in 2020, the Group was engaged in the fast moving consumer goods (“FMCG”) importation business into the PRC. Virax Cayman is a global innovative biotechnology group that primarily engages in sales, distribution and marketing of diagnostics test kits and med-tech and Personal Protective Equipment (“PPE”) products for the prevention, detection, diagnosis and risk management of viral diseases with a particular interest in the field of immunology. Our mission is to minimize the risks of viruses throughout the world via our products offerings. Our product portfolio includes: (i) diagnostics test kits sold through our “ViraxClear” brand; (ii) med-tech and PPE products sold through our “ViraxCare” brand; and (iii) sourced brands of third party suppliers, independent of our own brands (“Sourced Brands”). Currently, our Group does not manufacture or develop any product that we sell in our product portfolio and we act as a distributor of third-party suppliers’ products. We expect to develop and launch an upcoming brand “Virax Immune”, with the intention of providing an immunology profiling platform that assesses each individual’s immune risk profile against major global viral diseases. We believe that the T-Cell in-vitro diagnostic (“IVD”) Tests and immunology platform we are developing under the Virax Immune brand will be particularly useful in the diagnosis and threat analysis of the major viruses faced globally. As of the date of the prospectus, we have developed a functioning prototype of our T-Cell IVD Test under the Virax Immune brand but we are still in the process of conducting further tests and we have not submitted any T-Cell IVD Test to any regulatory agency for approval. Currently, our clinical trials and research activities for our T-Cell IVD Test under the Virax Immune brand are conducted by independent third party science companies, namely ICON Clinical Research Limited and IQ Services B.V., respectively, in the Netherlands. Prior to the sale of our T-Cell IVD Test under the Virax Immune brand in our targeted jurisdictions, namely, Canada, United Kingdom, the European Union and the United States, we must apply with the relevant authority for the regulatory approvals. In Canada, our T-Cell IVD Test will fall under Class I devices, which we will apply for the Health Canada Medical Device Establishment License. In the European Union, we intend to apply our T-Cell IVD Test under the self-certified Class A risk-based class route. Class A IVDs include specimen receptacles, laboratory instruments, and buffer solutions. Under the self-certified Class A risk-based class route, we do not require the involvement of a notified body to obtain the CE Marking to our T-Cell IVD Test. In the United Kingdom, as part of the transition due to the United Kingdom withdrawal from the European Union, we intend to use the recognized CE marks that we will apply with the European Union for our T-Cell IVD Test until June 30, 2023 (the “Transitional Arrangement”), after which, we will to conform with the UK IVD regime rather than relying on Transitional Arrangement and apply with the UK Medicine and Healthcare Products Regulatory Agency for a UK Conformity Assessed mark before we can sell our T-Cell IVD Test in the UK post June 30, 2023. In the United States, we intend to apply our T-Cell IVD Test under the Virax Immune brand under Class III devices (highest risk), which are subject to most of the requirements under Class I and Class II devices as well as to pre-market approval before they can be sold in the United States. Currently, our Group does not develop or manufacture any product that we sell under the ViraxCare brand, the ViraxClear brand and Sourced Brands as we act as a distributor of third-party suppliers’ products. To facilitate the sales and distribution of our ViraxClear and ViraxCare products, we predominately rely on our key third-party suppliers, Nanjing Vazyme Medical Technology Co., Ltd in China for diagnostics test kits and Venus Health Consulting Limited in Hong Kong for med-tech and PPE products, for product manufacturing. After we receive our ViraxCare and ViraxClear products from our suppliers, we utilize a third party logistic company, namely, Stork Up Limited in Hong Kong, for the distribution of our products to our end-users and strategic partners overseas. However, we believe our products, in particular diagnostic test kits, provide significant value for consumers, through improved detection of diseases, improvements in health, wellness and productivity as well as by reducing other healthcare costs, such as emergency visits and hospitalizations. Our Group also seeks to maximize consumers’ access to our products and services through competitive pricing and regular evaluations of our pricing arrangements and contracts with our distributors. Currently, the end-users of our distribution partners under our ViraxClear brand include but not limited to, clinics, pharmacies, laboratories, hospitals, and other relevant groups on an international basis, covering more than 10 countries and 4 regions, including but not limited to Europe, South America, Asia Pacific, and Sub-Saharan Africa, and Our Group expects to extend our geographical reach to North America in 2022, while the end-users of our dedicated online platforms sales under our ViraxClear brand are predominately individuals and pharmacies. The end-users of our ViraxCare products are predominately corporations, employees, and individual consumers. Currently, as stated above, clinical trials and research activities for our T-Cell IVD Test under the upcoming Virax Immune brand are conducted by independent third party science companies in the Netherlands together with our Hong Kong subsidiary, Virax Immune T-Cell. As our Group does not manufacture or develop any product that we sell under the ViraxCare brand, the ViraxClear brand and Sourced Brands because we act as a distributor of third-party suppliers’ products, the trading and sales of these products are primarily conducted through our SingaporeCo with some trading and sales of these products through our Logico BVI which are located in Singapore and British Virgin Islands, respectively. Shanghai Xitu is located in the PRC and is primarily engaged in procurement. Our principal executive office is located at 30 Broadwick Street London, W1F 8LX, United Kingdom. Our telephone number is +44 020 7788 7414. Our registered office in the Cayman Islands is located at the office of Ogier Global (Cayman) Limited, 89 Nexus Way, Camana Bay, Grand Cayman, KY1-9009, Cayman Islands. Our agent for service of process in the United States is Cogency Global Inc., located at 122 East 42nd Street, 18th Floor, New York, NY. Virax Biolabs Group Ltd (VRAX) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO James Foster and employs approximately 5 people. With a market capitalization of $2M, VRAX is one of the notable companies in the Healthcare sector.

Virax Biolabs Group Ltd (VRAX) Stock Rating — Avoid (April 2026)

As of April 2026, Virax Biolabs Group Ltd receives a Avoid rating with a composite score of 21.5/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.VRAX ranks #4,362 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Virax Biolabs Group Ltd ranks #807 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

VRAX Stock Price and 52-Week Range

Virax Biolabs Group Ltd (VRAX) currently trades at $0.17. The stock gained $0.04 (26.5%) in the most recent trading session. Recent trading volume was 56.7M shares, indicating strong institutional interest and high liquidity.

Is VRAX Overvalued or Undervalued? — Valuation Analysis

Virax Biolabs Group Ltd (VRAX) carries a value factor score of 22/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 0.18x, versus the sector average of 2.75x.

At current multiples, Virax Biolabs Group Ltd trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Virax Biolabs Group Ltd Profitability — ROE, Margins, and Quality Score

Virax Biolabs Group Ltd (VRAX) earns a quality factor score of 30/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -426.1%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -377.6% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

VRAX Debt, Balance Sheet, and Financial Health

Virax Biolabs Group Ltd has a debt-to-equity ratio of 6.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. Total debt on the balance sheet is $324,011. Cash and equivalents stand at $4M.

VRAX has a beta of 1.53, meaning it is more volatile than the broader market — a $10,000 investment in VRAX would be expected to move 53.0% more than the S&P 500 on any given day. The stability factor score for Virax Biolabs Group Ltd is 14/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Virax Biolabs Group Ltd Revenue and Earnings History — Quarterly Trend

In TTM 2026, Virax Biolabs Group Ltd reported revenue of $0 and earnings per share (EPS) of $-1.62. Net income for the quarter was $-6M. Operating income came in at $-6M.

In FY 2025, Virax Biolabs Group Ltd reported revenue of $0 and earnings per share (EPS) of $-1.62. Net income for the quarter was $-6M. Operating income came in at $-6M.

In FY 2024, Virax Biolabs Group Ltd reported revenue of $156,419. Net income for the quarter was $-7M. Gross margin was 32.3%. Revenue grew 1727.1% year-over-year compared to FY 2023. Operating income came in at $-6M.

In FY 2023, Virax Biolabs Group Ltd reported revenue of $8,561 and earnings per share (EPS) of $-0.51. Net income for the quarter was $-5M. Gross margin was -15.9%. Operating income came in at $-5M.

Over the past 6 quarters, Virax Biolabs Group Ltd has experienced revenue contraction from $123,820 to $0. Investors analyzing VRAX stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

VRAX Dividend Yield and Income Analysis

Virax Biolabs Group Ltd (VRAX) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

VRAX Momentum and Technical Analysis Profile

Virax Biolabs Group Ltd (VRAX) has a momentum factor score of 2/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 27/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 47/100 reflects moderate short selling activity.

VRAX vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Virax Biolabs Group Ltd (VRAX) ranks #807 out of 838 stocks based on the Blank Capital composite score. This places VRAX in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing VRAX against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full VRAX vs S&P 500 (SPY) comparison to assess how Virax Biolabs Group Ltd stacks up against the broader market across all factor dimensions.

VRAX Next Earnings Date

No upcoming earnings date has been announced for Virax Biolabs Group Ltd (VRAX) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy VRAX? — Investment Thesis Summary

The quantitative profile for Virax Biolabs Group Ltd suggests caution. The quality score of 30/100 flags below-average profitability. The value score of 22/100 indicates premium valuation. Momentum is weak at 2/100, a headwind for near-term performance. High volatility (stability score 14/100) increases portfolio risk.

In summary, Virax Biolabs Group Ltd (VRAX) earns a Avoid rating with a composite score of 21.5/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on VRAX stock.

Related Resources for VRAX Investors

Explore more research and tools: VRAX vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare VRAX head-to-head with peers: VRAX vs AZN, VRAX vs SLGL, VRAX vs VMD.